Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short term Debt (2016 - 2020)

Historic Short term Debt for Summit Therapeutics (SMMT) over the last 3 years, with Q1 2020 value amounting to -$102549.2.

  • Summit Therapeutics' Short term Debt changed N/A to -$102549.2 in Q1 2020 from the same period last year, while for Mar 2020 it was -$102549.2, marking a year-over-year change of. This contributed to the annual value of $105000.0 for FY2019, which is N/A changed from last year.
  • Per Summit Therapeutics' latest filing, its Short term Debt stood at -$102549.2 for Q1 2020.
  • Summit Therapeutics' 5-year Short term Debt high stood at -$98000.0 for Q3 2019, and its period low was -$1.1 million during Q4 2018.
  • Its 3-year average for Short term Debt is -$449215.7, with a median of -$102858.0 in 2019.
  • Over the last 5 years, Summit Therapeutics' Short term Debt had its largest YoY gain of 9113.38% in 2019, and its largest YoY loss of 9113.38% in 2019.
  • Summit Therapeutics' Short term Debt (Quarter) stood at -$1.1 million in 2018, then surged by 90.79% to -$102858.0 in 2019, then rose by 0.3% to -$102549.2 in 2020.
  • Its last three reported values are -$102549.2 in Q1 2020, -$102858.0 for Q4 2019, and -$99015.2 during Q4 2019.